MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Go back to MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 103.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $103.66 | 52 Week High | $118.49 | |||
| Open | $103.66 | 52 Week Low | $55.00 | |||
| Day High | $103.66 | P/E | N/A | |||
| Day Low | $103.66 | EPS | $-0.56 | |||
| Volume | 1,381 | |||||
